|

Nivolumab Injection [Opdivo] Clinical Trials

5 actively recruiting trials across 2 locations

Also known as: Nivolumab, carboplatin, paclitaxel

Pipeline

Phase 1: 1Phase 2: 4

Top Sponsors

  • Virogin Biotech Canada Ltd2
  • The First Affiliated Hospital of Guangzhou Medical University1
  • TaiRx, Inc.1
  • Inge Marie Svane1

Indications

  • Cancer5
  • Liver Disease2
  • Liver Cancer2
  • Hepatocellular Carcinoma2
  • Carcinoma, Squamous1

Other3 trials

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Phase 2
Melanoma Metastasized to the Brain and Steroids
Phase 2
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
Phase 2

Gilbert, Arizona1 trial

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Banner MD Anderson Cancer Center

Phase 1

Phoenix, Arizona1 trial

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Mayo Clinic

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.